J. Van Wyk, F. Ajana, F. Bisshop, S. De Wit, Y. Osiyemi, J. Portilla, . . . Y. El-Bahy. (2020). Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study). Elsevier.
Chicago Style (17th ed.) CitationJ. Van Wyk, et al. Switching to DTG/3TC Fixed-dose Combination (FDC) Is Non-inferior to Continuing a TAF-based Regimen in Maintaining Virologic Suppression Through 48 Weeks (TANGO Study). Elsevier, 2020.
MLA (9th ed.) CitationJ. Van Wyk, et al. Switching to DTG/3TC Fixed-dose Combination (FDC) Is Non-inferior to Continuing a TAF-based Regimen in Maintaining Virologic Suppression Through 48 Weeks (TANGO Study). Elsevier, 2020.
Warning: These citations may not always be 100% accurate.